Cargando…

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Suttle, A B, Ball, H A, Molimard, M, Hutson, T E, Carpenter, C, Rajagopalan, D, Lin, Y, Swann, S, Amado, R, Pandite, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264462/ http://dx.doi.org/10.1038/bjc.2014.627

Ejemplares similares

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
por: Suttle, A B, et al.
Publicado: (2014)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma
por: Ouerdani, A, et al.
Publicado: (2015)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma: Erratum
Publicado: (2014)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
por: Harrison, Michael R.
Publicado: (2011)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
por: Méndez-Vidal, María José, et al.
Publicado: (2018)

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study
por: Hamberg, P, et al.
Publicado: (2014)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Publicado: (2020)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
por: Xu, C-F, et al.
Publicado: (2010)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
por: Villa, Guillermo, et al.
Publicado: (2013)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
por: Plummer, Ruth, et al.
Publicado: (2012)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

Erratum to: Safety and efficacy of a 100 % dimethicone pediculocide in school-age children
por: Ihde, Erin Speiser, et al.
Publicado: (2016)

Erratum: “Is the Relationship between Prenatal Exposure to PCB-153 and Decreased Birth Weight Attributable to Pharmacokinetics?”
Publicado: (2014)

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck
por: Iberri, David J., et al.
Publicado: (2016)

Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma
por: Tomita, Yoshihiko, et al.
Publicado: (2021)

Erratum: Experimental assessment of the safety and potential efficacy of high irradiance photostimulation of brain tissues
por: Senova, Suhan, et al.
Publicado: (2017)

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
por: Pick, Amy M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1827c4rkl31vnpo1u0ci7sqvb1